Regeneron Files 8-K on Financial Results & Operations

TL;DR

**Regeneron just dropped an 8-K on financial results, get ready for potential stock movement.**

AI Summary

Regeneron Pharmaceuticals, Inc. filed an 8-K on February 2, 2024, to report on its results of operations and financial condition. This filing indicates that the company is providing an update on its financial performance, which is crucial for investors to understand the company's current health and future prospects. For shareholders, this matters because it offers transparency into how the company is performing, potentially influencing stock price based on whether the results meet or exceed expectations.

Why It Matters

This filing provides investors with the latest financial performance data for Regeneron, directly impacting their assessment of the company's value and future growth potential.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure of financial results and operations, not indicating any immediate new risks.

Analyst Insight

Investors should await the full financial statements and exhibits referenced in this 8-K to make informed decisions, as this filing only signals the release of such information.

Key Numbers

• February 2, 2024 — Date of Report (Indicates the effective date of the reported events and filing.)
• 000-19034 — Commission File Number (Unique identifier for Regeneron's filings with the SEC.)
• $.001 — Par Value per Share (The nominal value assigned to each share of common stock.)

Key Players & Entities

• REGENERON PHARMACEUTICALS, INC. (company) — the registrant filing the 8-K
• February 2, 2024 (date) — date of earliest event reported and filing date
• 000-19034 (other) — Commission File Number for Regeneron
• NASDAQ Global Select Market (other) — exchange where Regeneron's Common Stock is registered
• $.001 per share (dollar_amount) — par value of Regeneron's Common Stock

Forward-Looking Statements

• Regeneron's stock price will react to the detailed financial results once they are fully disclosed. (REGENERON PHARMACEUTICALS, INC.) — high confidence, target: Q1 2024

FAQ

From the Filing

0001804220-24-000006.txt : 20240202 0001804220-24-000006.hdr.sgml : 20240202 20240202071611 ACCESSION NUMBER: 0001804220-24-000006 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20240202 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240202 DATE AS OF CHANGE: 20240202 FILER: COMPANY DATA: COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000872589 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 133444607 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19034 FILM NUMBER: 24588794 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 BUSINESS PHONE: 9148477000 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 FORMER COMPANY: FORMER CONFORMED NAME: REGENERON PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 8-K 1 regn-20240202.htm 8-K regn-20240202 0000872589 false 0000872589 2024-02-02 2024-02-02 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2024 ( February 2, 2024 ) REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York 000-19034 13-3444607 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 777 Old Saw Mill River Road , Tarrytown , New York 10591-6707 (Address of Principal Executive Offices, including zip code) ( 914 ) 847-7000 Registrant's telephone number, including area code Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock - par value $.001 per share REGN NASDAQ Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 2.02     Results of Operations and Financial Condition. On February 2, 2024, Regeneron Pharmaceuticals, Inc. issued a press release announcing its financial and operating results for the quarter and year ended December 31, 2023. A copy of the press release is being furnished to the Securities and Exchange Commission as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference to this Item 2.02. The information included or incorporated in this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall such information and exhibit be deemed incorporated by reference in any filing under the Securities Act of 1933, a